A European Multi-centre, Retrospective, Non-interventional Study of the Effectiveness of Tresiba (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus

Trial Profile

A European Multi-centre, Retrospective, Non-interventional Study of the Effectiveness of Tresiba (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jun 2018

At a glance

  • Drugs Insulin degludec (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms EU-TREAT
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 26 Jun 2018 Results evaluating the effectiveness of degludec after switching from insulin glargine 100 units/mL (glargine U100), under routine care, presented at the 78th Annual Scientific Sessions of the American Diabetes Association.
    • 20 Mar 2018 Results presented at The 100th Annual Meeting of the Endocrine Society
    • 06 Nov 2017 According to a Novo Nordisk media release, new analysis of real-world data was presented today at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR 2017) 20th Annual European Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top